The accelerated approval for Hodgkin lymphoma was based on a single-arm multicentre clinical trial that enrolled 102 patients who had cluster of differentiation 30 (CD30)-positive Hodgkin lymphoma that relapsed after ASCT. Here, TNFRSF8 is linked to Hodgkins lymphoma.